Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
| Autor: | Hajime Maeda, Yasushi Tanaka, Masashi Ishikawa, Shin Honda, Tetsuya Motomiya, Ikuro Matsuba, Takehiro Kawata, Hideo Machimura, Kotaro Iemitsu, Atsuko Mokubo, Tetsuro Takuma, Hideaki Kaneshige, Akira Kanamori, Yasuyuki Jin, Kazuhiko Hoshino, Nobuaki Minami, Yasuo Terauchi, Mizuki Kaneshiro, Hikaru Amamiya, Nobuo Sasai, Yoshikazu Naka, Hiroshi Takeda, Shogo Ito, Akira Kubota, Kiyokazu Matoba, Sachio Aoyagi, Fuyuki Minagawa, Masahiko Takai, Manabu Waseda, Mitsuo Obana |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Combination therapy medicine.drug_class business.industry Endocrinology Diabetes and Metabolism nutritional and metabolic diseases General Medicine Type 2 diabetes Pharmacology Hypoglycemia medicine.disease Sulfonylurea chemistry.chemical_compound chemistry Sitagliptin Diabetes mellitus Internal medicine Internal Medicine medicine Glycated hemoglobin business Glycemic medicine.drug |
| Zdroj: | Journal of Diabetes Investigation. 3:503-509 |
| ISSN: | 2040-1116 2040-1124 |
| DOI: | 10.1111/j.2040-1124.2012.00221.x |
| Popis: | (J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00221.x, 2012) Aims/Introduction: To determine the efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients after 3 months’ therapy. Materials and Methods: A retrospective, observational study of 741 type 2 diabetes patients was carried out; 110 received sitagliptin monotherapy, and 631 received combination therapy with sitagliptin when other oral medications were insufficient. The primary outcome measure was glycated hemoglobin (HbA1c) measured at 0, 4 and 12 weeks of sitagliptin therapy. Results: In the monotherapy and combination therapy groups, HbA1c decreased significantly after 12 weeks. Target HbA1c ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|